Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• 12 U.S.C. § 1701g-5 — Revolving fund in connection with liquidating programs#564394
• Disproportionality analysis of sex-stratified adverse event signals in growth impairment: Insights from the FDA adverse event reporting system.#388720
• D4.1 tunES Tool for EPBD Policy Measures on EPC, SRI and BRP#164258
• A control-function approach to correct for endogeneity in discrete choice models estimated on SP-off-RP data and contrasts with an earlier FIML approach by Train & Wilson#646928
• Tracking economic change over a decade: an analysis of Austria's industry-sponsored clinical trial landscape and implications for policy.#275994